Skip to main content
SpringerLink
Log in

Lifestyle and Medical Approaches to Cancer Prevention

  • Conference paper
Tumor Prevention and Genetics III

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 166))

Abstract

Cancer risk can be reduced by adopting a healthy lifestyle and by medical means. Tobacco control is central to public policies for cancer prevention. Overweight and obesity in the United States may contribute to 20% of cancer deaths in women and 14% in men. Cancer prevention strategies have progressed from a predominant lifestyle approach to a model that combines clinical investigations in a medical setting with public health interventions. This change stems from advances in identifying, developing, and testing agents with the potential either to prevent cancer initiation, or to inhibit or reverse the progression of premalignant lesions to invasive cancer. Encouraging laboratory and epidemiologic studies, along with secondary endpoints in treatment trials, have provided a strong scientific rationale for the hypothesis that a pharmacologic approach—chemoprevention—can reduce cancer risk. Numerous chemopreventive agents, including naturally occurring vitamins, minerals, phytochemicals, and synthetic compounds, have proved to be safe and effective in preclinical and clinical studies. Promising results have been reported for cancers of the prostate, breast, colon, lung, bladder, cervix, oral cavity, esophagus, skin, and liver. The use of emerging technologies, identification of biomarkers of risk, and advances in genetic research are being applied to chemoprevention research. An interdisciplinary research approach to investigate molecular and genetic markers—as well as chemoprevention and lifestyle strategies—that affect cancer risk is being applied to the most common types of cancer in the United States in women (breast) and men (prostate).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Anthony M, Dunn BK, Sherman S (eds) (2001) Selective estrogen receptor modulators. Ann NY Acad Sci 949:1–427

    Google Scholar 

  • Brawley OW, Knopf K, Thompson I (1998) The epidemiology of prostate cancer part II: the risk factors. Semin Urol Oncol 16:193–201

    PubMed  CAS  Google Scholar 

  • Buzdar A, O’shaughnessy JA, Booser DJ, Pippen JE Jr, Jones SE, Munster PN, Peterson P, Melemed AS, Winer E, Hudis C (2003) Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol 21:1007–1014

    Article  PubMed  CAS  Google Scholar 

  • Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr (1999) Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 341:1097–1105

    Article  PubMed  CAS  Google Scholar 

  • Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638

    Article  PubMed  Google Scholar 

  • Chan JM, Stampfer MJ, Ma J, Rimm EB, Willett WC, Giovannucci EL (1999) Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev 8: 893–899

    PubMed  CAS  Google Scholar 

  • Chemoprevention Working Group (1999) Prevention of cancer in the next millennium: report of the Chemoprevention Working Group to the American Association for Cancer Research. Cancer Res 59:4743–4758

    Google Scholar 

  • Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL Jr, Park HK, Sanders BB Jr, Smith CL, Taylor JR (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276:1957–1963

    Article  PubMed  CAS  Google Scholar 

  • Clark LC, Dalkin B, Krongrad A, Combs GF Jr, Turnbull BW, Slate EH, Witherington R, Herlong JH, Janosko E, Carpenter D, Borosso C, Falk S, Rounder J (1998) Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol 81:730–734

    PubMed  CAS  Google Scholar 

  • Community Intervention Trial for Smoking Cessation (COMMIT) (1995) I. Cohort results from a four-year community intervention. Changes in adult cigarette smoking prevalence. Am J Public Health 85:183–192

    Google Scholar 

  • Doll R, Peto R (1981) The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 66:1191–1308

    PubMed  CAS  Google Scholar 

  • Fabian CJ (2001) Breast cancer chemoprevention: beyond tamoxifen. Breast Cancer Res 3:99–103

    Article  PubMed  CAS  Google Scholar 

  • Fabian CJ, Kimler BF (2002) Breast cancer chemoprevention: current challenges and a look toward the future. Clin Breast Cancer 3: 113–124

    Article  PubMed  Google Scholar 

  • Feigl P, Blumenstein B, Thompson I, Crowley J, Wolf M, Kramer BS, Coltman CA Jr, Brawley OW, Ford LG (1995) Design of the Prostate Cancer Prevention Trial (PCPT). Controlled Clin Trials 16:150–163

    PubMed  CAS  Google Scholar 

  • Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:371–388

    Article  Google Scholar 

  • GLOBOCAN (2000) Cancer incidence, mortality and prevalence worldwide, version 1.0. IARC CancerBase No. 5. IARCPress, Lyon. Web site at http://www-dep.iarc.fr/globocan/globocan.html

    Google Scholar 

  • Greenwald P, Nixon DW, Malone WF, Kelloff GJ, Stern HR, Witkin KM (1990) Concepts in cancer chemoprevention research. Cancer 65: 1483–1490

    PubMed  CAS  Google Scholar 

  • Greenwald P (2001) From carcinogenesis to clinical interventions for cancer prevention. Toxicology 166:37–45

    Article  PubMed  CAS  Google Scholar 

  • Greenwald P (2002a) Cancer chemoprevention. BMJ 324:714–718

    Article  PubMed  CAS  Google Scholar 

  • Greenwald P (2002b) Cancer prevention clinical trials. J Clin Oncol 20(18 Suppl): 14S–22S

    PubMed  CAS  Google Scholar 

  • Greenwald P, Kelloff G, Burch-Whitman C, Kramer BS (1995) Chemoprevention. CA Cancer J Clin 45:31–49

    Article  PubMed  CAS  Google Scholar 

  • Haiman CA, Stampfer MJ, Giovannucci E, Ma J, Decalo NE, Kantoff PW, Hunter DJ (2001) The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiol Biomarkers Prev 10:743–748

    PubMed  CAS  Google Scholar 

  • Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, Haapakoski J, Malila N, Rautalahti M, Ripatti S, Maenpaa H, Teerenhovi L, Koss L, Virolainen M, Edwards BK (1998) Prostate cancer and supplementation with α-tocopherol and β-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 90:440–446

    Article  PubMed  CAS  Google Scholar 

  • Higginson J (1988) Changing concepts in cancer prevention: limitations and implications for future research in environmental carcinogenesis. Cancer Res 48:1381–1389

    PubMed  CAS  Google Scholar 

  • Hoque A, Albanes D, Lippman SM, Spitz MR, Taylor PR, Klein EA, Thompson IM, Goodman P, Stanford JL, Crowley JJ, Coltman CA, Santella RM (2001) Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes Control 12: 627–633

    Article  PubMed  CAS  Google Scholar 

  • Huang M-T, Asawa T, Ho C-T, Rosen RT (eds) (1994) Food phytochemicals for cancer prevention I—fruits and vegetables, vol. 54. ACS Symposium Series No. 546, American Chemical Society: Washington, DC. Wiley, John and Sons, New York, pp1–426

    Google Scholar 

  • Hursting SD, Lavigne JA, Berrigan D, Perkins SN, Barrett JC (2003) Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. Annu Rev Med 54:131–152 (Epub 2001)

    Article  PubMed  CAS  Google Scholar 

  • Kaluzny AD, Ricketts T 3rd, Warnecke R, Ford L, Morrissey J, Gillings D, Sondik EJ, Ozer H, Goldman J (1989) Evaluating organizational design to assure technology transfer: the case of the Community Clinical Oncology Program. J Natl Cancer Inst 81:1717–1725

    PubMed  CAS  Google Scholar 

  • Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albanes D, Taylor PR, Coltman C (2001) SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. J Urol 166: 1311–1315

    CAS  Google Scholar 

  • Krishnamurthy S, Sneige N (2002) Molecular and biologic markers of premalignant lesions of human breast. Adv Anat Pathol 9:185–197

    PubMed  Google Scholar 

  • Levin ML, Goldstein H, Gerhardt PR (1950) Cancer and tobacco smoking: a preliminary report. JAMA 143:336–338

    CAS  Google Scholar 

  • Li CI, Malone KE, Daling JR (2002) Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev 11:601–607

    PubMed  Google Scholar 

  • Manley M, Lynn W, Epps RP, Grande D, Glynn T, Shopland D (1997a) The American Stop Smoking Intervention Study for cancer prevention: an overview. Tob Control 6:S5–S11

    PubMed  Google Scholar 

  • Manley MW, Pierce JP, Gilpin EA, Rosbrook B, Berry C, Wun LM (1997b) Impact of the American Stop Smoking Intervention Study on cigarette consumption. Tob Control 6 (Suppl 2): S12–S16

    PubMed  Google Scholar 

  • McTiernan A (2003) Behavioral risk factors in breast cancer: can risk be modified? Oncologist 8:326–334

    Article  PubMed  Google Scholar 

  • Mokbel K (2002) The evolving role of aromatase inhibitors in breast cancer. Int J Clin Oncol 7:279–283

    PubMed  CAS  Google Scholar 

  • Negri E, La Vecchia CL, Franceschi S, D’Avanzo B, Parazzini F (1991) Vegetable and fruit consumption and cancer risk. Int J Cancer 48:350–354

    PubMed  CAS  Google Scholar 

  • Pandey M, Mathew A, Nair MK (1999) Global perspective of tobacco habits and lung cancer: a lesson for third world countries. Eur J Cancer Prev 8:271–279

    PubMed  CAS  Google Scholar 

  • Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ (2003) The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8: 307–325

    Article  PubMed  CAS  Google Scholar 

  • Schwartz KL, Crossley-May H, Vigneau FD, Brown K, Banerjee M (2003) Race, socioeconomic status and stage at diagnosis for five common malignancies. Cancer Causes Control 14:761–766

    Article  PubMed  Google Scholar 

  • Shin BK, Wang H, Hanash S (2003) Proteomics approaches to uncover the repertoire of circulating biomarkers for breast cancer. J Mammary Gland Biol Neoplasia 7:407–413

    Google Scholar 

  • Steele VE (2003) Current mechanistic approaches to the chemoprevention of cancer. J Biochem Mol Biol 36:78–81

    PubMed  CAS  Google Scholar 

  • Steele VE, Moon RC, Lubet RA, Grubbs CJ, Reddy BS, Wargovich M, McCormick DL, Pereira MA, Crowell JA, Bagheri D, Sigman CC, Boone CW, Kelloff GJ (1994) Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: methods and results from the NCI chemoprevention drug development program. J Cell Biochem Suppl 20:32–54

    PubMed  CAS  Google Scholar 

  • Stillman FA, Hartman AM, Graubard BI, Gilpin EA, Murray DM, Gibson JT (2003) Evaluation of the American Stop Smoking Intervention Study (ASSIST): a report of outcomes. J Natl Cancer Inst 95:1681–1691

    PubMed  Google Scholar 

  • Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349: 215–224

    Article  PubMed  CAS  Google Scholar 

  • Thun MJ, Henley SJ, Calle EE (2002) Tobacco use and cancer: an epidemiologic perspective for geneticists. Oncogene 21:7307–7325

    Article  PubMed  CAS  Google Scholar 

  • U.S. Department of Health and Human Services (1964) Smoking and health: a report of the Advisory Committee to the Surgeon General of the Public Health Service.U.S. Department of Health, Education, and Welfare, Centers for Disease Control, Atlanta

    Google Scholar 

  • U.S. Department of Health and Human Services (1998) Tobacco use among U.S. racial/ ethnic minority groups—African Americans, American Indians and Alaska natives, Asian Americans and Pacific islanders, and Hispanics: a report of the Surgeon General. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta

    Google Scholar 

  • Verma M, Srivastava S (2003) New cancer biomarkers deriving from NCI early detection research. Recent Results Cancer Res 163:72–84

    PubMed  CAS  Google Scholar 

  • von Eschenbach AC (2003) NCI sets goal of eliminating suffering and death due to cancer by 2015. J Natl Med Assoc 95:637–639

    Google Scholar 

  • Wynder EL, Graham EA (1950) Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma. A study of 684 proved cases. JAMA 143:329–336

    CAS  Google Scholar 

  • Ye SQ, Usher DC, Zhang LQ (2002) Gene expression profiling of human diseases by serial analysis of gene expression. J Biomed Sci 9: 384–394

    Article  PubMed  CAS  Google Scholar 

  • Yip TT, Lomas L (2002) SELDI ProteinChip array in oncoproteomic research. Technol Cancer Res Treat 1:273–280

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 6130 Executive Boulevard, Suite 2040, Bethesda, MD, 20892-7309, USA

    Peter Greenwald

Authors
  1. Peter Greenwald
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Zentrum für Tumordiagnostik und Prävention, Rorschacherstrasse 150, 9006, St. Gallen, Switzerland

    Hans-Jörg Senn  & Rudolf Morant  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Greenwald, P. (2005). Lifestyle and Medical Approaches to Cancer Prevention. In: Senn, HJ., Morant, R. (eds) Tumor Prevention and Genetics III. Recent Results in Cancer Research, vol 166. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26980-0_1

Download citation

  • DOI: https://doi.org/10.1007/3-540-26980-0_1

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-22228-6

  • Online ISBN: 978-3-540-26980-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation